Seqirus opens U.K. office; Mitsubishi Tanabe plans U.S. flu vaccine;

> CSL's flu vaccine unit Seqirus opened a U.K. corporate office. Release

> Japan's Mitsubishi Tanabe Pharma plans to focus on increasing its U.S. sales, with one component of its strategy involving a flu vaccine currently under development. Report

> A paper in PLOS Medicine argues in favor of a compensation system for vaccine injuries for cases such as the Ebola outbreak in which vaccines must be tested rapidly without hesitation due to liability. More

Suggested Articles

GSK's Shingrix supply has recovered after COVID-19 prompted a slowdown in vaccinations.

To eradicate SARS-CoV-2, we'll need a vaccine that's 70% effective—and 70% of the population will need to receive it, an FDA official says.

The U.K. government, fearing losing the supply race, agreed to buy 60 million doses of GSK-Sanofi's COVID-19 vaccine even before phase 1.